Medicare plans are replacing brand-name buprenorphine-naloxone film with its generic equivalents, resulting in a decrease in out-of-pocket cost faced by enrollees with opioid use disorder. Objectives: ...
“Buprenorphine HCl buccal film represents a novel approach to treating chronic pain and if approved, it will be the first and only pain medicine combining the proven efficacy and safety of ...
The US Food and Drug Administration (FDA) has approved the first generic versions of Suboxone (buprenorphine and naloxone) sublingual film for the treatment of opioid dependence, which may increase ...
The authors write "Suboxone is the brand name of combination of Buprenorphine and Naloxone, manufactured by Indivior, Inc., and used in the treatment of opioid dependence. In January of 2022, the FDA ...
SAINT LAURENT, Quebec, April 05, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”) today announced that its co-developer, Chemo Research SL, through its ...
New treatment option combines proven efficacy and established safety profile of buprenorphine with a novel delivery system that adds convenience and flexibility Endo Pharmaceuticals Inc., a subsidiary ...
Add Yahoo as a preferred source to see more of our stories on Google. The Wisconsin Department of Justice along with 40 other states and the District of Columbia has settled a lawsuit for $102.5 ...
INDV is set to report Q4 results on Feb. 26, with focus on Sublocade sales and pipeline updates. Indivior expects continued Sublocade growth, though Suboxone film may face generic pressure. INDV ...
On October 19, 2022, U.S. District Judge Mitchell Goldberg in the Eastern District of Pennsylvania granted Aquestive Therapeutics Inc.’s (f/k/a MonoSol Rx LLC) motion for summary judgment in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results